Chennai-based pharmaceuticals major Orchid Chemicals & Pharmaceuticals Ltd has received approval from the Food and Drug Administration (FDA) of the US for its infectious diseases drug.
The company said in a release Friday that the FDA has approved its abbreviated new drug application for Cefpodoxime Proxetil tablets.
The product is available in two dosage strengths of 100 mg and 200 mg.
Cefpodoxime Proxetil is a third-generation cephalosporin antibiotic, which has broad-spectrum activity against organisms causing infectious diseases.
With limited generic competition in this product, Orchid hopes to garner a sizeable market share and revenues in the US market, the company said Friday.